Literature DB >> 15510596

Overexpression of the Wilms' tumor gene WT1 in esophageal cancer.

Yusuke Oji1, Masahiko Yano, Yoko Nakano, Sakie Abeno, Shin-Ichi Nakatsuka, Ai Ikeba, Takushi Yasuda, Yoshiyuki Fujiwara, Shuji Takiguchi, Hirofumi Yamamoto, Seiichiro Fujita, Keisuke Kanato, Ken Ito, Tanyarat Jomgeow, Manabu Kawakami, Akihiro Tsuboi, Toshiaki Shirakata, Sumiyuki Nishida, Naoki Hosen, Yoshihiro Oka, Katsuyuki Aozasa, Morito Monden, Haruo Sugiyama.   

Abstract

BACKGROUND: The Wilms' tumor gene WT1 is overexpressed in various kinds of solid cancers. However, it remains unclear whether WT1 is expressed in esophageal squamous cell carcinoma.
MATERIALS AND METHODS: Expression of the WT1 gene was examined by real-time RT-PCR in 12 esophageal squamous cell carcinoma (ESCC) and by immunohistochemistry in 9 of these 12 and another 29.
RESULTS: Real-time RT-PCR showed that the WT1 mRNA was overexpressed in all of the 12 ESCC examined Immunohistochemical analysis showed that the WT1 protein was overexpressed in ESCC cells in 36 (95%) of the 38 examined Furthermore, expression of the WT1 protein was examined in 20 esophageal squamous dysplasia. The WT1 protein was overexpressed in 5 (45%) out of 11 mild dysplasia and in 8 (89%) out of 9 moderate to severe dysplasia.
CONCLUSION: These results may indicate an important role of the WT1 gene in the tumorigenesis of ESCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15510596

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

2.  Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Authors:  N Tatsumi; N Hojo; O Yamada; M Ogawa; Y Katsura; S Kawata; E Morii; H Sakamoto; R Inaba; A Tsuda; I Fukuda; N Moriguchi; H Hasuwa; M Okabe; F Fujiki; S Nishida; H Nakajima; A Tsuboi; Y Oka; N Hosen; H Sugiyama; Y Oji
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

3.  Dual use of a single Wilms' tumor 1 immunohistochemistry in evaluation of ovarian tumors: a preliminary study of 20 cases.

Authors:  Yi-Hsuan Hsiao; Sarwat Siddiqui; Yan-Gao Man
Journal:  J Cancer       Date:  2010-07-13       Impact factor: 4.207

4.  Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Tsunekazu Kita; Kazunari Maekawa; Kazuyuki Fujii; Kazuya Kudoh; Kenichi Furuya; Seiichi Tamai; Johji Inazawa; Osamu Matsubara
Journal:  Virchows Arch       Date:  2007-06-27       Impact factor: 4.064

5.  Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer.

Authors:  Tatsuo Matsuda; Hiroya Takeuchi; Toshiharu Sakurai; Shuhei Mayanagi; Eisuke Booka; Tomonobu Fujita; Hajime Higuchi; Junichi Taguchi; Yasuo Hamamoto; Hiromasa Takaishi; Hirofumi Kawakubo; Masato Okamoto; Makoto Sunamura; Yutaka Kawakami; Yuko Kitagawa
Journal:  Oncol Lett       Date:  2018-05-17       Impact factor: 2.967

6.  Denys-Drash syndrome associated WT1 glutamine 369 mutants have altered sequence-preferences and altered responses to epigenetic modifications.

Authors:  Hideharu Hashimoto; Xing Zhang; Yu Zheng; Geoffrey G Wilson; Xiaodong Cheng
Journal:  Nucleic Acids Res       Date:  2016-09-04       Impact factor: 16.971

7.  Role for first zinc finger of WT1 in DNA sequence specificity: Denys-Drash syndrome-associated WT1 mutant in ZF1 enhances affinity for a subset of WT1 binding sites.

Authors:  Dongxue Wang; John R Horton; Yu Zheng; Robert M Blumenthal; Xing Zhang; Xiaodong Cheng
Journal:  Nucleic Acids Res       Date:  2018-05-04       Impact factor: 16.971

8.  The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.

Authors:  Youqi Han; Serban San-Marina; Lin Yang; Haytham Khoury; Mark D Minden
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

9.  In silico regulatory analysis for exploring human disease progression.

Authors:  Dustin T Holloway; Mark Kon; Charles DeLisi
Journal:  Biol Direct       Date:  2008-06-18       Impact factor: 4.540

10.  The Wilms' tumour suppressor protein WT1 acts as a key transcriptional repressor of the human thromboxane A2 receptor gene in megakaryocytes.

Authors:  AnneMarie M Gannon; B Therese Kinsella
Journal:  J Cell Mol Med       Date:  2009 Nov-Dec       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.